Test Result | Canary Oncoceutics Canary Acuity | Canary Oncoceutics Canary Lumina | Company A | Company B | Company C | Company D | Company E |
---|---|---|---|---|---|---|---|
# of Genes Analyzed via NGS | 1091 (+637 Variants) | DNA + RNA | 302 | 341 | 517 | 523 | 648 |
Therapeutic SNVs and INDELS | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Amplifications and Deletions | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Fusions genes | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Tumor Mutational Burden (TMB) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Microsatellite Instability (MSI) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
TCR Clonality | ✓ | ✓ | |||||
Homologous Recombination Deficiency (HRD) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
Loss of Heterozygosity (LOH) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
Comprehensive proprietary database of FDA approved/clinical trial drugs for corresponding biomarkers | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Depiction of cancer-relevant pathways | ✓ | ✓ | |||||
Germline variants affecting drug metabolism | ✓ | ✓ | |||||
Complete ACMG Oncology Germline Mutational Analysis | ✓ | ✓ | |||||
ImmunoInsightTM score (Tumor Immunogenicity) | ✓ | ||||||
Tumor Lymphoid Structures Levels (TLS) | ✓ | ||||||
Tumor Infiltrating Lymphocytes (TILs) | ✓ | ||||||
Therapeutic Response Prediction | ✓ | ||||||
Overall Survival Prediction | ✓ |
Canary AcuityTM | Company A |
---|---|
Tumor Mutation Burden (1091 genes)” | Tumor Mutation Burden (324 genes) |
Microsatellite Instability (1091 genes + 51 markers) | Microsatellite Instability (324 genes) |
TCR Clonality (110 genes) | N/A |
20 E Thomas Road, Suite 2203, Phoenix, Arizona, 85012, USA
1-888-909-9809